3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
48
Lung Neoplasms
24
Carcinoma, Hepatocellular
24
Small Cell Lung Carcinoma
16
Urinary Bladder Neoplasms
12
Cholangiocarcinoma
12
Breast Neoplasms
10
Biliary Tract Neoplasms
10
Neoplasms
9
Neoplasm Metastasis
9
Liver Neoplasms
9
Pancreatic Neoplasms
7
Carcinoma
6
Endometrial Neoplasms
5
Colorectal Neoplasms
5
Triple Negative Breast Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Neoplasms by Site
4
Gallbladder Neoplasms
4
Carcinoma, Transitional Cell
4
Stomach Neoplasms
3
Respiratory Tract Neoplasms
3
Ovarian Neoplasms
3
Carcinoma, Renal Cell
3
Bile Duct Neoplasms
3
Adenocarcinoma
3
Thyroid Neoplasms
2
Thoracic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Interventions
Cisplatin
14
Paclitaxel
12
pembrolizumab
9
Fluorouracil
7
Radiotherapy
6
Irinotecan
5
Esophagectomy
5
tislelizumab
4
Oxaliplatin
4
Leucovorin
4
Drug Therapy
4
Carboplatin
4
toripalimab
3
Levoleucovorin
3
Docetaxel
3
Capecitabine
3
camrelizumab
2
Taxes
2
Radiation
2
Nivolumab
2
Injections
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
sintilimab
1
palbociclib
1
nimotuzumab
1
nazartinib
1
lenvatinib
1
ivarmacitinib
1
futibatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
durvalumab
×
90 days
×
Clear all
NCT04550260
2026-05-13
KUNLUN
AstraZeneca
Phase 3
Active not recruiting
640 enrolled